Clinical trials in Libramont-Chevigny

Study of Bemarituzumab with Chemotherapy and Nivolumab in Untreated Advanced Gastric and Gastroesophageal Junction Cancer Patients with FGFR2b Overexpression

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Bemarituzumab
Sponsor:Amgen Inc.

Contact Research Centre

Study of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:AstraZeneca AB

Contact Research Centre

Bladder transitional cell carcinoma

Not recruiting

Registered drugNo placebo

Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Cetrelimab
Sponsor:Janssen - Cilag International

Contact Research Centre

Other cities in Belgium

The busiest research cities in the country

All 170 cities in Belgium

Colorectal cancer metastatic 3 Gastric cancer 2 Oesophageal adenocarcinoma 2 Adenocarcinoma gastric 1 Bladder transitional cell carcinoma 1 Breast cancer metastatic 1 Ductal adenocarcinoma of pancreas 1 Endometrial cancer 1 Gastrooesophageal cancer 1 Hepatobiliary cancer 1 Non-small cell lung cancer 1 Non-small cell lung cancer metastatic 1 Oesophageal carcinoma 1 Oesophageal squamous cell carcinoma 1 Ovarian cancer recurrent 1 Ovarian epithelial cancer 1 Small cell lung cancer 1 Small cell lung cancer limited stage 1 Squamous cell carcinoma of head and neck 1 Triple negative breast cancer 1

Infliximab 4 Mycophenolate Mofetil 4 Pembrolizumab 4 Capecitabine 3 Durvalumab 3 Datopotamab Deruxtecan 2 Docetaxel 2 Fluorouracil 2 HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST FOLR1 CONJUGATED TO 1-[(2R,3R,4R,5S,52S)-1,2,3,4,5-PENTAHYDROXY-52-{[(2S)-1-{[(2S)-5-CARBAMOYLAMINO-1-OXO-1-{3-[({[(1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12HBENZO[DE]PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-1-YL]CARBAMOYL}OXY)METHYL]ANILINO}PENTAN-2-YL]AMINO}-3-METHYL-1-OXOBUTAN-2-YL]CARBAMOYL}-7-[(2S,3R,4R,5R)-2,3,4,5,6-PENTAHYDROXYHEXYL]-46,54-DIOXO10,13,16,19,22,25,28,31,34,37,40,43-DODECAOXA-7,47,53-TRIAZANONAPENTACONTAN-59-YL]-2,5-DIOXOPYRROLIDIN-3-YL 2 Olaparib 2 Oxaliplatin 2 Paclitaxel 2 AZD5335 1 Bemarituzumab 1 Bevacizumab 1 Calcium Folinate 1 Carboplatin 1 Ceralasertib 1 Cetrelimab 1 Cyclophosphamide 1

Clinical research in Libramont-Chevigny

What the registry says about research in the country

01 Libramont-Chevigny

Neoplasms (Cancer)

In Libramont-Chevigny, Belgium, the three actively recruiting studies concentrate on neoplasms, addressing some of the most challenging solid‑tumor indications. Researchers are evaluating novel combination immunotherapies, genetic vaccine strategies, and targeted agents to improve outcomes for patients with advanced cancers. Locally advanced unresectable or metastatic microsatellite instability‑high (MSI‑H) or dMMR colorectal cancer Recurrent or metastatic head and neck squamous cell carcinoma Relapsed small cell lung cancer Combination approaches such as zanzalintinib with pembrolizumab and investigational genetic vaccines These trials aim to demonstrate enhanced anti‑tumor activity, higher response rates, and longer survival compared with standard therapies, offering hope for patients facing limited treatment options.

Clinical trials in Libramont-Chevigny – page 2

15 trials in Libramont-Chevigny

Gastric cancer

Study of Bemarituzumab with Chemotherapy and Nivolumab in Untreated Advanced Gastric and Gastroesophageal Junction Cancer Patients with FGFR2b Overexpression

Triple negative breast cancer

Study of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer

Bladder transitional cell carcinoma

Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

Filter the trials

Other cities in Belgium

Clinical research in Libramont-Chevigny

Prefer not to search? Our Concierge searches the trials for you.

Clinical trials in Libramont-Chevigny – page 2

15 trials in Libramont-Chevigny

Gastric cancer

Study of Bemarituzumab with Chemotherapy and Nivolumab in Untreated Advanced Gastric and Gastroesophageal Junction Cancer Patients with FGFR2b Overexpression

Triple negative breast cancer

Study of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer

Bladder transitional cell carcinoma

Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

Other cities in Belgium

Related

Clinical research in Libramont-Chevigny

Prefer not to search? Our Concierge searches the trials for you.